Published 2013
| Version v1.0.0
Journal Article
Open
Immunomodulatory Therapy for Rasmussen Syndrome
Creators
Abstract
Investigators from the National Epilepsy Center, Shizuoka, Gifu University, Tokyo Womens Medical University, National Center of Neurology and Psychiatry, and Okayama University School of Medicine, Japan, examined seizure, cognitive, and motor outcomes in 49 patients referred with Rasmussen encephalitis (RS) and recently had received initial immunomodulatory therapy: regular IV immunoglobulin (IVIg) at a dose of 100 mg/kg/day, methylprednisolone steroid pulse therapy at a dose of 30 mg/kg/day (children) for 3 days, and tacrolimus 0.1 mg/kg/day.Files
PNB-2013-27-10-9.pdf
Files
(94.3 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:5d881e45358bf4cd1944133e279705e3
|
94.3 kB | Preview Download |
Additional details
Identifiers
- Other
- PNB-2013-27-10-9
Dates
- Created
-
2013When the item was originally created.